<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814890</url>
  </required_header>
  <id_info>
    <org_study_id>2011QD10</org_study_id>
    <nct_id>NCT02814890</nct_id>
  </id_info>
  <brief_title>Thoracic Paravertebral Block Using Ropivacaine and Dexmedetomidine</brief_title>
  <official_title>Thoracic Paravertebral Block Using Ropivacaine With/Without Dexmedetomidine in Video-assisted Pneumonectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jianghui Xu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the study is whether dexmedetomidine plus local anesthetic ropivacaine&#xD;
      could extend the pain relieve time compared with only ropivacaine when thoracic paravertebral&#xD;
      block is performed at the end of video-assisted pneumonectomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to recruit 60 patients undergoing video-assisted pneumonectomy. All&#xD;
      patients ASA physical status I-II grade, aged within 20-70 years, are randomly allocated into&#xD;
      two groups: 75mg/20ml ropivacaine only group (Group R, n=30) and 75mg/20ml ropivacaine +&#xD;
      1μg/kg dexmedetomidine (Group RD, n=30). At the end of surgery, the investigators perform&#xD;
      four points thoracic paravertebral block guided by ultrasound combined with nerve stimulator&#xD;
      at T3-4, T4-5, T5-6, T6-7 of surgical side where 5ml solution is injected to each point. The&#xD;
      characteristics of patients are analyzed to confirm whether they are comparable in both&#xD;
      groups. Pain was assessed according to a numerical rating scale (NRS) (0 = no pain; 10 =&#xD;
      worst pain imaginable). Patients were asked to evaluate the maximal degree of pain. Pain&#xD;
      scores were recorded in post anesthesia care unit(PACU), and1, 2,4, 8, 12, 24, 36 and 48&#xD;
      hours after surgery. The study endpoints are evaluated by an anesthesiologist who does not&#xD;
      know the group allocation. The postoperative rescue analgesic administration, adverse&#xD;
      outcomes and patient satisfaction are also recorded.&#xD;
&#xD;
      All data were processed in SPSS 18.0 (SPSS Inc., Chicago, IL USA). Normality was tested by&#xD;
      the Kolmogorov-Smirnov analysis. Comparisons of continuous outcomes among groups were&#xD;
      examined using Kruskal-Wallis test. Chi-square analysis or Fisher's exact test was used to&#xD;
      assess categorical outcomes between groups. A P-value&lt;0.05 was considered statistically&#xD;
      significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain (Pain Scores) Intensity Measure</measure>
    <time_frame>assessed over 48 hours after surgery, self reported pain intensity at 2 days reported</time_frame>
    <description>Pain Numerical Rating Scales （NRS) at rest（0: no pain--means the minimum value; 10: worst possible pain--means the maximum value)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>Hour 48 after surgery</time_frame>
    <description>using a 5-point Likert scale (5-point: completely satisfied, 4-point: quite satisfied, 3-point: slightly dissatisfied, 2-point: dissatisfied, 1-point: very dissatisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postoperative Rescue Analgesic Administration</measure>
    <time_frame>Hour 24, Hour 48 after surgery</time_frame>
    <description>a rescue analgesic morphine 5mg will be administered for any pain score ≥4 （0: no pain--means the minimum value; 10: worst possible pain--means the maximum value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Hour 48 after surgery</time_frame>
    <description>including nausea, vomiting, hypotension, bradycardia, and respiratory depression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Ropivacaine and dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Video-assisted Pneumonectomy</intervention_name>
    <description>Video-assisted Pneumonectomy under general anesthesia.</description>
    <arm_group_label>Ropivacaine and dexmedetomidine</arm_group_label>
    <arm_group_label>Ropivacaine only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracic paravertebral block</intervention_name>
    <description>The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.</description>
    <arm_group_label>Ropivacaine and dexmedetomidine</arm_group_label>
    <arm_group_label>Ropivacaine only</arm_group_label>
    <other_name>Thoracic paravertebral nerve block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA physical status I-II grade&#xD;
&#xD;
          -  Undergoing elective video-assisted pneumonectomy under general anesthesia.&#xD;
&#xD;
          -  Participants aged from 30-70 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal for paravertebral block&#xD;
&#xD;
          -  Inability to obtain informed consent&#xD;
&#xD;
          -  Coagulation disorders, neuropathy, or body mass index greater than 40 kg/m2&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Infections at the site of injection for the paravertebral block&#xD;
&#xD;
          -  Allergy to local anesthetics or alpha-2 adrenergic agonists&#xD;
&#xD;
          -  Heart block or bradycardia (heart rate &lt; 60 beat per minute)&#xD;
&#xD;
          -  Clinically significant cardiovascular, pulmonary, renal, or hepatic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology,Huashan Hospital,Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huashan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <results_first_submitted>August 29, 2017</results_first_submitted>
  <results_first_submitted_qc>August 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2020</results_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Jianghui Xu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Thoracic paravertebral block</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Video-assisted Pneumonectomy</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Pain, Postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty-five patients were initially recruited in Auguest, 2016.</recruitment_details>
      <pre_assignment_details>The participants who were converted to thoracotomy because of intraoperative bleeding or pleural adhesions would be wash out.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group RD(Ropivacaine and Dexmedetomidine)</title>
          <description>Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.&#xD;
Video-assisted Pneumonectomy: Video-assisted Pneumonectomy under general anesthesia.&#xD;
Thoracic paravertebral block: The procedure is guided by ultrasound combined with nerve stimulator at T4-5, T5-6, T6-7, T7-8 of surgical side.&#xD;
Sixty-five patients were initially recruited. Five patients were excluded from present study, including 3 patients in group RD who were converted to thoracotomy because of intraoperative bleeding or pleural adhesions.</description>
        </group>
        <group group_id="P2">
          <title>Group R(Ropivacaine Only)</title>
          <description>Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.&#xD;
Video-assisted Pneumonectomy: Video-assisted Pneumonectomy under general anesthesia.&#xD;
Thoracic paravertebral block: The procedure is guided by ultrasound combined with nerve stimulator at T4-5, T5-6, T6-7, T7-8 of surgical side.&#xD;
Sixty-five patients were initially recruited. Five patients were excluded from present study, including 2 patients in group R who were converted to thoracotomy because of intraoperative bleeding or pleural adhesions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group RD(Ropivacaine and Dexmedetomidine)</title>
          <description>Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.&#xD;
Video-assisted Pneumonectomy: Video-assisted Pneumonectomy under general anesthesia.&#xD;
Thoracic paravertebral block: The procedure is guided by ultrasound combined with nerve stimulator at T4-5, T5-6, T6-7, T7-8 of surgical side.&#xD;
There were no significant differences between two groups in demographic and operative data(Gender, Age, Weight, Height, ASA（Ⅰ/Ⅱ), FEV1 (% predicted), FEV1/FVC (% predicted), Intraoperative fentanyl, Duration of surgery, Duration of anesthesia).</description>
        </group>
        <group group_id="B2">
          <title>Group R(Ropivacaine Only)</title>
          <description>Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.&#xD;
Video-assisted Pneumonectomy: Video-assisted Pneumonectomy under general anesthesia.&#xD;
Thoracic paravertebral block: The procedure is guided by ultrasound combined with nerve stimulator at T4-5, T5-6, T6-7, T7-8 of surgical side.&#xD;
There were no significant differences between two groups in demographic and operative data(Gender, Age, Weight, Height, ASA（Ⅰ/Ⅱ), FEV1 (% predicted), FEV1/FVC (% predicted), Intraoperative fentanyl, Duration of surgery, Duration of anesthesia).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Measure Analysis Population Description: 5 patients were excluded due to their type of surgery transfering from VATS to thoracotomy, in which 3 patients in Group RD and 2 ones in Group R.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>recruited number of participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="33"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="9.6"/>
                    <measurement group_id="B2" value="59.7" spread="9.4"/>
                    <measurement group_id="B3" value="59.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>analyzed number of participants</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="9.7"/>
                    <measurement group_id="B2" value="59.5" spread="9.7"/>
                    <measurement group_id="B3" value="59.3" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>5 patients were excluded due to their type of surgery transfering from VATS to thoracotomy, in which 3 patients in Group RD and 2 ones in Group R.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain (Pain Scores) Intensity Measure</title>
        <description>Pain Numerical Rating Scales （NRS) at rest（0: no pain--means the minimum value; 10: worst possible pain--means the maximum value)</description>
        <time_frame>assessed over 48 hours after surgery, self reported pain intensity at 2 days reported</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group RD(Ropivacaine and Dexmedetomidine)</title>
            <description>The pain scores (numerical rating scale, NRS) postoperative 48h at rest and coughing were assessed.</description>
          </group>
          <group group_id="O2">
            <title>Group R(Ropivacaine Only)</title>
            <description>The pain scores (numerical rating scale, NRS) postoperative 48h at rest and coughing were assessed.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain (Pain Scores) Intensity Measure</title>
          <description>Pain Numerical Rating Scales （NRS) at rest（0: no pain--means the minimum value; 10: worst possible pain--means the maximum value)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size: Based on our previous data, pain score at rest 48 hours postoperatively when using ropivacaine only was of 2.8 with a standard deviation of 1.4. Assuming a decrease of pain score by 1.1 being clinically significant, twenty six patents in each group would be required for a study power of 80% (α=0.05,β=0.2). Considering possible dropouts, we aimed at recruiting 30 patients in each group with a total of 60 patients.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>difference test</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>using a 5-point Likert scale (5-point: completely satisfied, 4-point: quite satisfied, 3-point: slightly dissatisfied, 2-point: dissatisfied, 1-point: very dissatisfied)</description>
        <time_frame>Hour 48 after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group RD(Ropivacaine and Dexmedetomidine)</title>
            <description>Patients' satisfaction were assessed verbally 48 hours after surgery using a 5- point Likert scale (5=completely satisfied, 4=quite satisfied, 3=slightly dissatisfied, 2=dissatisfied, 1=very dissatisfied).</description>
          </group>
          <group group_id="O2">
            <title>Group R(Ropivacaine Only)</title>
            <description>Patients' satisfaction were assessed verbally 48 hours after surgery using a 5- point Likert scale (5=completely satisfied, 4=quite satisfied, 3=slightly dissatisfied, 2=dissatisfied, 1=very dissatisfied).</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>using a 5-point Likert scale (5-point: completely satisfied, 4-point: quite satisfied, 3-point: slightly dissatisfied, 2-point: dissatisfied, 1-point: very dissatisfied)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 point of 5- point Likert scale</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 point of 5- point Likert scale</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 point of 5- point Likert scale</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 point of 5- point Likert scale</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 point of 5- point Likert scale</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>difference test</non_inferiority_desc>
            <param_type>Kendall's tau-b correlation coefficient</param_type>
            <param_value>0.470</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postoperative Rescue Analgesic Administration</title>
        <description>a rescue analgesic morphine 5mg will be administered for any pain score ≥4 （0: no pain--means the minimum value; 10: worst possible pain--means the maximum value)</description>
        <time_frame>Hour 24, Hour 48 after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group RD(Ropivacaine and Dexmedetomidine)</title>
            <description>An extra rescue analgesic morphine 5 mg was given when the NRS was ≥ 4 at rest. The time of the first rescue analgesic requirement and the total morphine consumption in the first 48 hours were recorded.</description>
          </group>
          <group group_id="O2">
            <title>Group R(Ropivacaine Only)</title>
            <description>An extra rescue analgesic morphine 5 mg was given when the NRS was ≥ 4 at rest. The time of the first rescue analgesic requirement and the total morphine consumption in the first 48 hours were recorded.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Rescue Analgesic Administration</title>
          <description>a rescue analgesic morphine 5mg will be administered for any pain score ≥4 （0: no pain--means the minimum value; 10: worst possible pain--means the maximum value)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>including nausea, vomiting, hypotension, bradycardia, and respiratory depression</description>
        <time_frame>Hour 48 after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group RD(Ropivacaine and Dexmedetomidine)</title>
            <description>Postoperative adverse effects such as nausea, vomiting, hypotension, hypoxemia, cardiac arrhythmia and the complications from the drugs and technique (local anesthetic toxicity, vascular puncture) were recorded and treated.</description>
          </group>
          <group group_id="O2">
            <title>Group R(Ropivacaine Only)</title>
            <description>Postoperative adverse effects such as nausea, vomiting, hypotension, hypoxemia, cardiac arrhythmia and the complications from the drugs and technique (local anesthetic toxicity, vascular puncture) were recorded and treated.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>including nausea, vomiting, hypotension, bradycardia, and respiratory depression</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.64</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Postoperative 48h adverse effects such as nausea, vomiting, hypotension, hypoxemia, cardiac arrhythmia and the complications from the drugs and technique (local anesthetic toxicity, vascular puncture) were recorded and treated.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group RD(Ropivacaine and Dexmedetomidine)</title>
          <description>Postoperative adverse effects such as nausea, vomiting, hypotension, hypoxemia, cardiac arrhythmia and the complications from the drugs and technique (local anesthetic toxicity, vascular puncture) were recorded and treated.</description>
        </group>
        <group group_id="E2">
          <title>Group R(Ropivacaine Only)</title>
          <description>Postoperative adverse effects such as nausea, vomiting, hypotension, hypoxemia, cardiac arrhythmia and the complications from the drugs and technique (local anesthetic toxicity, vascular puncture) were recorded and treated.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>nausea and vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jun Zhang</name_or_title>
      <organization>Huashan Hospital, Fudan University, Shanghai</organization>
      <phone>0086-021-52887694</phone>
      <email>snapzhang@aliyun.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

